CTRI/2025/02/080850RecruitingNot Applicable
A Randomized, Double-Blind, Placebo-Controlled Clinical Study to assess the effect of Libifema (VL-GF-01) on Fertility in Women with Diminished Ovarian Reserve
Vedic Lifesciences Pvt. Ltd12 sites in 1 country150 target enrollmentStarted: March 30, 2025Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Vedic Lifesciences Pvt. Ltd
- Enrollment
- 150
- Locations
- 12
- Primary Endpoint
- To assess the effect of the Investigational product (IP) on time to pregnancy (TTP) as assessed by serum levels of Beta-human Chorionic Gonadotropin (Beta-hCG).
Study Overview
Brief Summary
The present study is a randomized, double-blind, placebo-controlled, parallel clinical study. Approximately 156 participants will be screened, and considering a screening failure rate of 20%, not more than 124 participants will be randomized in a ratio of 1:1 to receive either Libifem® or placebo and will be assigned a unique randomization code. Each group will have not less than 50 completed participants after accounting for a dropout/withdrawal rate of 20%.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Masking
- Participant, Investigator and Outcome Assessor Blinded
Eligibility Criteria
- Ages
- 25.00 Year(s) to 35.00 Year(s) (—)
- Sex
- Female
Inclusion Criteria
- •1.Individuals ready to give voluntary, written informed consent to participate in the study
- •Women of age between 25 to 35 years who wish to conceive
- •Women with BMI between 18.5 to 34.9 kg/m2 (both values included)
- •Women who are unable to conceive for at least one year with an unprotected sexual life
- •Women engaging in sexual act regularly and agree to continue the same at least twice a week during the study
- •Women with bilateral tubal patency as confirmed by reports (within last one year from screening) of Hysterosalpingography (HSG) or Sonosalpingography (SSG)
- •Eumenorrheic women with a regular menstrual cycle of 28 ± 5 days.
- •Women with Hemoglobin levels greater than or equal to
- •Women with Anti-Mullerian hormone (AMH) greater than 0 and less than 1.5 ng/ml on day 2 of menstrual cycle
- •Females with serum Thyroid-stimulating hormone (TSH) levels between 0.4 mIU/L to 5 mIU/L [both values inclusive] with or without medication.
- •Women who are not pregnant during the time of screening as assessed by UPT
- •Women who have never undergone IVF procedure
- •Women with their male partners having an acceptable serum analysis report as per PI
- •Women willing to complete all study-related assessments and to complete all clinical study visits as per the protocol.10 g/dL.
Exclusion Criteria
- •Any chronic illness like hyper-prolactinemia
- •Females diagnosed with stage 3 and stage 4 Endometriosis
- •Females with a history of recurrent pregnancy loss (defined as ≥ 2 failed clinical pregnancies before 22 weeks of gestational age).
- •Females clinically diagnosed with Polycystic Ovarian Syndrome (PCOS).
- •Females with a prior history (within the last 6 months from screening) of ≥3 cycles of ovulation induction.
- •History of ovarian hyper-response.
- •History of any endocrine abnormality (eg: Adrenal gland disorders, pituitary disorders, endocrine diseases, dyslipidemia, etc.).
- •Females previously diagnosed with hyperparathyroidism and/or hyperthyroidism.
- •Females with a history of any psychiatric disorder.
- •Currently undergoing or have previously undergone Hormone Therapy (HT) for treatment of fertility in the previous 6 monthS
- •Currently consuming Ayurvedic/dietary supplements, and/or currently consuming steroids or if consumed in the last 3 months before screening.
- •Currently consuming cytotoxics and immunosuppressants.
- •History of uncontrolled hypertension and/or systolic blood pressure greater than equal to 140 mmHg and/or diastolic blood pressure greater than equal to 90 mmHg.
- •Fasting blood glucose (FBG) greater than or equal to 126 mg/dL.
- •Participation in other clinical studies in the past 3 months.
- •History of alcohol or drug abuse in the 12 months prior to screening.
- •History of cancer.
- •Hematological disorders.
- •20.History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential individual at risk because of participation in the study History or presence of HIV, cardiovascular, gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
- •Lactating women.
Outcomes
Primary Outcomes
To assess the effect of the Investigational product (IP) on time to pregnancy (TTP) as assessed by serum levels of Beta-human Chorionic Gonadotropin (Beta-hCG).
Time Frame: 4 menstrual cycles from randomization
Secondary Outcomes
- To assess the impact of the IP as compared to baseline and placebo on:(1.Ovulation status as assessed by Antral follicle count (AFC) using Transvaginal ultrasonography (TVS) [On day 2 & day 10 of each menstrual cycle])
Investigators
Dr Sanjay Vaze
Vedic Lifesciences Pvt Ltd
Study Sites (12)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07292714Mabwell (Shanghai) Bioscience Co., Ltd.360
Not yet recruiting
Phase 2
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus NephritisLupus NephritisNCT07393451Simcere Pharmaceutical Co., Ltd60
Not yet recruiting
Phase 3
A Clinical study to test if Pinorox® (Pine Bark Extract) capsules are safe and helpful for improving memory and thinking in older adults with age-related memory problems.CTRI/2025/07/091775Ambe Phytoextracts Pvt Ltd86
Completed
Phase 3
The Efficacy and Safety of Reconyl in Acute Cough TreatmentNCT07420491Dexa Medica Group144
Not yet recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07313917Longbio Pharma150